Items where Author is "Borsari, Chiara"

Article

Borsari, Chiara and Keles, Erhan and Treyer, Andrea and De Pascale, Martina and Hebeisen, Paul and Hamburger, Matthias and Wymann, Matthias P.. (2021) Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability. RSC Medicinal Chemistry, 12 (4). pp. 579-583.

Borsari, Chiara and Keles, Erhan and Rageot, Denise and Treyer, Andrea and Bohnacker, Thomas and Bissegger, Lukas and De Pascale, Martina and Melone, Anna and Sriramaratnam, Rohitha and Beaufils, Florent and Hamburger, Matthias and Hebeisen, Paul and Löscher, Wolfgang and Fabbro, Doriano and Hillmann, Petra and Wymann, Matthias P.. (2020) 4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of neurological disorders. Journal of Medicinal Chemistry, 63 (22). pp. 13595-13617.

Uliassi, Elisa and Piazzi, Lorna and Belluti, Federica and Mazzanti, Andrea and Kaiser, Marcel and Brun, Reto and Moraes, Carolina B. and Freitas-Junior, Lucio H. and Gul, Sheraz and Kuzikov, Maria and Ellinger, Bernhard and Borsari, Chiara and Costi, Maria Paola and Bolognesi, Maria Laura. (2018) Development of a focused library of triazole-linked privileged-structure-based conjugates leading to the discovery of novel phenotypic hits against protozoan parasitic infections. ChemMedChem, 13 (7). pp. 678-683.

Beaufils, Florent and Cmiljanovic, Natasa and Cmiljanovic, Vladimir and Bohnacker, Thomas and Melone, Anna and Marone, Romina and Jackson, Eileen and Zhang, Xuxiao and Sele, Alexander and Borsari, Chiara and Mestan, Jurgen and Hebeisen, Paul and Hillmann, Petra and Giese, Bernd and Zvelebil, Marketa and Fabbro, Doriano and Williams, Roger L. and Rageot, Denise and Wymann, Matthias P.. (2017) 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Journal of Medicinal Chemistry, 60 (17). pp. 7524-7538.